{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:51:05Z","timestamp":1764330665322,"version":"3.46.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04376-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:48:56Z","timestamp":1764330536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Mengting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiju","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"4376_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01698-y","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025;18(1):42.","journal-title":"J Hematol Oncol"},{"key":"4376_CR2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.883","volume":"12","author":"M Casamayor","year":"2018","unstructured":"Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883.","journal-title":"Ecancermedicalscience"},{"key":"4376_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine. 2022;47:101404.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"4376_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90064-6","volume":"15","author":"SE Mousavi","year":"2025","unstructured":"Mousavi SE, Ilaghi M, Elahi Vahed I, Nejadghaderi SA. Epidemiology and socioeconomic correlates of gastric cancer in Asia: results from the GLOBOCAN 2020 data and projections from 2020 to 2040. Sci Rep. 2025;15(1):6529.","journal-title":"Sci Rep"},{"key":"4376_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.927030","volume":"9","author":"J Sun","year":"2022","unstructured":"Sun J, Nan Q. Survival benefit of surgical resection for stage IV gastric cancer: a SEER-based propensity score-matched analysis. Front Surg. 2022;9:927030.","journal-title":"Front Surg"},{"issue":"4","key":"4376_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179\u2013203.","journal-title":"Cancer Metastasis Rev"},{"key":"4376_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071336","author":"MK Scheck","year":"2024","unstructured":"Scheck MK, Hofheinz RD, Lorenzen S. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16071336.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4376_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"4376_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0759","volume":"86","author":"H Yuan","year":"2025","unstructured":"Yuan H, Bao M, Chen M, Fu J, Yu S. Advances in immunotherapy and targeted therapy for gastric cancer: a comprehensive review. Br J Hosp Med. 2025;86(3):1\u201324.","journal-title":"Br J Hosp Med"},{"issue":"1","key":"4376_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"issue":"1","key":"4376_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03508-0","volume":"24","author":"X Lei","year":"2024","unstructured":"Lei X, Huo W, Xu T, et al. Efficacy and safety of nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2024;24(1):422.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4376_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03754-w","volume":"25","author":"X Ji","year":"2025","unstructured":"Ji X, Wang G, Pan D, Xu S, Lei X. Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):173.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"4376_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","volume":"266","author":"S Leucht","year":"2016","unstructured":"Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266(6):477\u201380.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"11","key":"4376_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"4376_CR15","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.","journal-title":"BMJ (Clinical Res ed)"},{"key":"4376_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. J Wiley-Blackwell; 2008.","DOI":"10.1002\/9780470712184"},{"key":"4376_CR17","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2019;366:l4898.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"10","key":"4376_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.","journal-title":"PLoS One"},{"issue":"4","key":"4376_CR19","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","volume":"24","author":"N Boku","year":"2021","unstructured":"Boku N, Satoh T, Ryu MH, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2021;24(4):946\u201358.","journal-title":"Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"6","key":"4376_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895\u2013902.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4376_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","volume":"23","author":"LT Chen","year":"2020","unstructured":"Chen LT, Satoh T, Ryu MH. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23(3):510\u20139.","journal-title":"Gastric Cancer"},{"issue":"5","key":"4376_CR22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/cncr.34019","volume":"128","author":"HC Chung","year":"2022","unstructured":"Chung HC, Kang YK, Chen Z, et al. Pembrolizumab versus Paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer. 2022;128(5):995\u20131003.","journal-title":"Cancer"},{"issue":"1","key":"4376_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","volume":"25","author":"CS Fuchs","year":"2022","unstructured":"Fuchs CS, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Pembrolizumab versus Paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022;25(1):197\u2013206.","journal-title":"Gastric Cancer"},{"issue":"7890","key":"4376_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"10294","key":"4376_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"2","key":"4376_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4376_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4376_CR28","unstructured":"!!! INVALID CITATION !!!."},{"issue":"1","key":"4376_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","volume":"22","author":"E Catanzaro","year":"2025","unstructured":"Catanzaro E, Beltr\u00e1n-Visiedo M, Galluzzi L, Krysko DV. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol. 2025;22(1):24\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4376_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/cas.16061","volume":"115","author":"M Hosonuma","year":"2024","unstructured":"Hosonuma M, Hirasawa Y, Kuramasu A, et al. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer Sci. 2024;115(3):752\u201362.","journal-title":"Cancer Sci"},{"issue":"21","key":"4376_CR31","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"issue":"12","key":"4376_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7224","volume":"13","author":"F Pei","year":"2024","unstructured":"Pei F, He W, Duan Y, et al. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR\/MSS colorectal cancer. Cancer Med. 2024;13(12):e7224.","journal-title":"Cancer Med"},{"issue":"8","key":"4376_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443\u201351.","journal-title":"mAbs"},{"issue":"1","key":"4376_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100036","volume":"6","author":"F Pietrantonio","year":"2021","unstructured":"Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036.","journal-title":"ESMO Open"},{"issue":"7","key":"4376_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s10147-024-02515-1","volume":"29","author":"K Hiraizumi","year":"2024","unstructured":"Hiraizumi K, Honda C, Watanabe A, et al. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan. Int J Clin Oncol. 2024;29(7):932\u201343.","journal-title":"Int J Clin Oncol"},{"key":"4376_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, et al. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024;15:1447021.","journal-title":"Front Immunol"},{"issue":"5","key":"4376_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.343","volume":"4","author":"L Wang","year":"2023","unstructured":"Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4(5):e343.","journal-title":"MedComm"},{"key":"4376_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102209","volume":"51","author":"SA Kim","year":"2025","unstructured":"Kim SA, Kim S, Hong Y, et al. Immunogenic clearance combined with PD-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8(+)T cell. Transl Oncol. 2025;51:102209.","journal-title":"Transl Oncol"},{"issue":"10302","key":"4376_CR39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"1","key":"4376_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1037-z","volume":"14","author":"E Eriksson","year":"2016","unstructured":"Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G. Gemcitabine reduces MDSCs, Tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer. J Transl Med. 2016;14(1):282.","journal-title":"J Transl Med"},{"key":"4376_CR41","first-page":"117590","volume-title":"Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy","author":"Y Qi","year":"2024","unstructured":"Qi Y, Zhang L, Liu Y, Li Y, Liu Y, Zhang Z. Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy, vol. 180. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie; 2024. p. 117590."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04376-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:49:00Z","timestamp":1764330540000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04376-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4376"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04376-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not include the participant\u2019s identification image or other personal or clinical details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"847"}}